Physician
Pediatrics
Dr. Mark E. McGovern, MD
|
|
Give Review
Dr. Mark E. McGovern works in the field of Pediatrics. He went to Creighton University School of Medicine. Creighton University School of Medicine is ranked 79 in research and 78 in primary care medicine He received 1 awards: "Fellow (FACC)". Dr. Mark E. McGovern is a published doctor. He has 30 publications published. The most current publication "Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I)."
Publications
- Optimal pharmacotherapy to combat the atherogenic lipid triad.
- Optimal management of persistent mixed dyslipidemia after statin initiation warrants combination therapy.
- Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project).
- Taking aim at HDL-C. Raising levels to reduce cardiovascular risk.
- Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).
- Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
- Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B,...
- Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis.
- A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
- Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin an...
- Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
- Gliclazide: the effects on lipids in type II diabetes.
- Effect of food on pravastatin pharmacokinetics and pharmacodynamics.
- Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).
- Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.
- Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome.
- Long-term experience with pravastatin in clinical research trials.
- Pravastatin experience in elderly and non-elderly patients.
- Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia.
- Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)
- Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.
- A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Pravastatin Multination...
- Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.
- Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation.
- Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148.
- Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).
- Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agent...
- Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes contro...
- Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
Schools
Creighton University
Cincinnati Childrens Hospital
Doctors Specialties
- Pediatrics
Accepted Insurances
- Aetna
- CareSource
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Coventry Health America PPO
- First Health (Coventry Health Care) PPO
- Golden Rule
- GEHA
- Choice Care PPO
- Managed Care (Non-HMO)
- Medical Mutual of Ohio
- Medicare MCR
- MultiPlan
- NGS CoreSource
- United Healthcare
Awards
- Fellow (FACC)
Education
-
Cincinnati Children's Hospital Medical Center -
Creighton University School of Medicine
Hospital
-
Cincinnati Children's Hospital Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Michael T. Vossmeyer, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shana R. Alexander, MD |
|
|
Dr. Raymond C. Baker, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sharon A. Dsouza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kelley A. Barney, MD |
|
|
Dr. Philip A. Hagedorn, MD |
|
|
Dr. Clara F. Chlon, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert S. Kahn, MD |
|
|
Dr. Lauren T. Huff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristen A. Copeland, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Megan C. Hennigan, MD
This Doctor is OpenDoctor Recommended.
|